265 related articles for article (PubMed ID: 25183703)
1. Linking signaling pathways to transcriptional programs in breast cancer.
Osmanbeyoglu HU; Pelossof R; Bromberg JF; Leslie CS
Genome Res; 2014 Nov; 24(11):1869-80. PubMed ID: 25183703
[TBL] [Abstract][Full Text] [Related]
2. Elucidating the altered transcriptional programs in breast cancer using independent component analysis.
Teschendorff AE; Journée M; Absil PA; Sepulchre R; Caldas C
PLoS Comput Biol; 2007 Aug; 3(8):e161. PubMed ID: 17708679
[TBL] [Abstract][Full Text] [Related]
3. Logic-based analysis of gene expression data predicts association between TNF, TGFB1 and EGF pathways in basal-like breast cancer.
Jo K; Santos-Buitrago B; Kim M; Rhee S; Talcott C; Kim S
Methods; 2020 Jul; 179():89-100. PubMed ID: 32445696
[TBL] [Abstract][Full Text] [Related]
4. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
Bild AH; Parker JS; Gustafson AM; Acharya CR; Hoadley KA; Anders C; Marcom PK; Carey LA; Potti A; Nevins JR; Perou CM
Breast Cancer Res; 2009; 11(4):R55. PubMed ID: 19638211
[TBL] [Abstract][Full Text] [Related]
5. Inferring coregulation of transcription factors and microRNAs in breast cancer.
Wu JH; Sun YJ; Hsieh PH; Shieh GS
Gene; 2013 Apr; 518(1):139-44. PubMed ID: 23246694
[TBL] [Abstract][Full Text] [Related]
6. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
[TBL] [Abstract][Full Text] [Related]
7. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.
Gatza ML; Kung HN; Blackwell KL; Dewhirst MW; Marks JR; Chi JT
Breast Cancer Res; 2011 Jun; 13(3):R62. PubMed ID: 21672245
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive tissue-specific gene set enrichment analysis and transcription factor analysis of breast cancer by integrating 14 gene expression datasets.
Li WX; He K; Tang L; Dai SX; Li GH; Lv WW; Guo YC; An SQ; Wu GY; Liu D; Huang JF
Oncotarget; 2017 Jan; 8(4):6775-6786. PubMed ID: 28036274
[TBL] [Abstract][Full Text] [Related]
9. Unraveling transcriptional regulatory programs by integrative analysis of microarray and transcription factor binding data.
Li H; Zhan M
Bioinformatics; 2008 Sep; 24(17):1874-80. PubMed ID: 18586698
[TBL] [Abstract][Full Text] [Related]
10. An efficient algorithm to identify coordinately activated transcription factors.
Hu H
Genomics; 2010 Mar; 95(3):143-50. PubMed ID: 20060041
[TBL] [Abstract][Full Text] [Related]
11. Subtype and pathway specific responses to anticancer compounds in breast cancer.
Heiser LM; Sadanandam A; Kuo WL; Benz SC; Goldstein TC; Ng S; Gibb WJ; Wang NJ; Ziyad S; Tong F; Bayani N; Hu Z; Billig JI; Dueregger A; Lewis S; Jakkula L; Korkola JE; Durinck S; Pepin F; Guan Y; Purdom E; Neuvial P; Bengtsson H; Wood KW; Smith PG; Vassilev LT; Hennessy BT; Greshock J; Bachman KE; Hardwicke MA; Park JW; Marton LJ; Wolf DM; Collisson EA; Neve RM; Mills GB; Speed TP; Feiler HS; Wooster RF; Haussler D; Stuart JM; Gray JW; Spellman PT
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2724-9. PubMed ID: 22003129
[TBL] [Abstract][Full Text] [Related]
12. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Berns K; Horlings HM; Hennessy BT; Madiredjo M; Hijmans EM; Beelen K; Linn SC; Gonzalez-Angulo AM; Stemke-Hale K; Hauptmann M; Beijersbergen RL; Mills GB; van de Vijver MJ; Bernards R
Cancer Cell; 2007 Oct; 12(4):395-402. PubMed ID: 17936563
[TBL] [Abstract][Full Text] [Related]
13. Sense-antisense gene-pairs in breast cancer and associated pathological pathways.
Grinchuk OV; Motakis E; Yenamandra SP; Ow GS; Jenjaroenpun P; Tang Z; Yarmishyn AA; Ivshina AV; Kuznetsov VA
Oncotarget; 2015 Dec; 6(39):42197-221. PubMed ID: 26517092
[TBL] [Abstract][Full Text] [Related]
14. Profiling activities of transcription factors in breast cancer cell lines.
Jiang X; Roth L; Lai C; Li X
Assay Drug Dev Technol; 2006 Jun; 4(3):293-305. PubMed ID: 16834535
[TBL] [Abstract][Full Text] [Related]
15. A novel framework for inferring condition-specific TF and miRNA co-regulation of protein-protein interactions.
Zhang J; Le TD; Liu L; He J; Li J
Gene; 2016 Feb; 577(1):55-64. PubMed ID: 26611531
[TBL] [Abstract][Full Text] [Related]
16. Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines.
Niepel M; Hafner M; Pace EA; Chung M; Chai DH; Zhou L; Schoeberl B; Sorger PK
Sci Signal; 2013 Sep; 6(294):ra84. PubMed ID: 24065145
[TBL] [Abstract][Full Text] [Related]
17. Characterizing disease states from topological properties of transcriptional regulatory networks.
Tuck DP; Kluger HM; Kluger Y
BMC Bioinformatics; 2006 May; 7():236. PubMed ID: 16670008
[TBL] [Abstract][Full Text] [Related]
18. Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.
Sonnenblick A; Brohée S; Fumagalli D; Vincent D; Venet D; Ignatiadis M; Salgado R; Van den Eynden G; Rothé F; Desmedt C; Neven P; Loibl S; Denkert C; Joensuu H; Loi S; Sirtaine N; Kellokumpu-Lehtinen PL; Piccart M; Sotiriou C
BMC Med; 2015 Aug; 13():177. PubMed ID: 26234940
[TBL] [Abstract][Full Text] [Related]
19. Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers.
Osmanbeyoglu HU; Shimizu F; Rynne-Vidal A; Alonso-Curbelo D; Chen HA; Wen HY; Yeung TL; Jelinic P; Razavi P; Lowe SW; Mok SC; Chiosis G; Levine DA; Leslie CS
Nat Commun; 2019 Sep; 10(1):4369. PubMed ID: 31554806
[TBL] [Abstract][Full Text] [Related]
20. Regression analysis of combined gene expression regulation in acute myeloid leukemia.
Li Y; Liang M; Zhang Z
PLoS Comput Biol; 2014 Oct; 10(10):e1003908. PubMed ID: 25340776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
